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Abstract 
Frontotemporal dementia (FTD), the second most common type of presenile dementia, is characterized by   
progressive behavioral and/or language problems. It is a heterogeneous neurodegenerative disease, and 
includes a range of clinical, genetic and pathological subtypes. This heterogeneity hampers the diagnostic 
process, which is becoming increasingly important for future clinical trials on disease-modifying 
treatments. Reliable biomarkers will enable us to better discriminate FTD from other forms of dementia 
and predict disease progression in the clinical setting. As different underlying pathologies probably 
require specific pharmacological interventions, robust biomarkers are essential to select patients with 
specific FTD subtypes. This review emphasizes the increasing availability and potential applications of 
imaging (structural and functional)  and fluid biomarkers (CSF and blood) in sporadic and genetic FTD. 
The relevance of new MRI modalities such as VBM, DTI and ASL in the early stages of FTD is 
discussed, together with their ability to classify FTD subtypes. We highlight promising new fluid 
biomarkers for staging and monitoring FTD, underlining the importance of large, multicenter studies of 
presymptomatic FTD subjects. Crucial for the implementation of new biomarkers in clinical practice, is 
the harmonization in collecting and analyzing across different centers, which will become a great 
challenge for the next years.  
Introduction  
Frontotemporal dementia (FTD) is the second most common form of dementia in people aged under 65 
and encompasses two main clinical manifestations: behavioral changes with executive dysfunction 
(‘behavioral FTD’, bvFTD) or predominant language impairment (‘primary progressive aphasia’, PPA) 
(Text Box 1).1,2 PPAs can be further divided in the semantic variant (svPPA), non-fluent variant (nfvPPA) 
and logopenic variant (lvPPA).2 Patients may develop concomitant parkinsonism or motor neuron disease 
(MND) at an early or late stage, resulting in a broad clinical phenotype ranging from amyotrophic lateral 
sclerosis (ALS) to progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) (Figure 1).3 
Patients presenting with nfvPPA may develop characteristic features of PSP or CBS over time, while 
lvPPA is frequently associated with underlying Alzheimer’s disease (AD).  
Postmortem examination of the brain shows frontotemporal lobar degeneration (FTLD) with either tau 
(FTLD-tau), TAR DNA-binding protein 43 (FTLD-TDP), or fused in sarcoma inclusions (FTLD-FUS).3 
Correlation between the clinical presentation and specific underlying pathology is poor in bvFTD and 
better in svPPA and FTD-MND, both associated with TDP pathology.4 Patients who develop symptoms 
consistent with PSP or CBS, often exhibit FTLD-tau at post-mortem examination. In contrast to sporadic 
FTD, the underlying pathology in genetic FTD can accurately be predicted (Figure 1). 
FTD is highly heritable and 10-20% of all cases are caused by mutations in three genes: microtubule-
associated protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72).3 
Other, rare, FTLD genes include charged multivesicular body protein 2B (CHMP2B), valosin containing 
protein (VCP), sequestosome 1 (SQSTM1), transactive response DNA-binding protein (TARDP), and the 
more recently identified TANK-binding kinase 1 gene (TBK-1).5Although some phenotypes are 
associated with specific mutations, e.g. the co-occurence of MND with C9orf72 mutations, genotype-
phenotype correlations are generally poor, even within families.3  
Sensitive biomarkers are crucial for FTD because of its heterogeneity. Great efforts to identify these 
biomarkers have been made over the last two decades, with a predominant focus on fluid biomaterial and 
neuroimaging features. The ideal biomarker should meet the following criteria, according to previous 
consensus: 1) able to detect a fundamental pathological feature of the disease, 2) validated in pathological 
proven cohorts, 3) precise, 4) reliable, 5) non-invasive, 6) simple to perform, and 7) inexpensive (Text 
Box 2).6 Different biomarkers can be used for specific purposes (Text Box 2), and therefore the value of a 
biomarker depends on its application. In FTD, diagnostic biomarkers should discriminate FTD from 
controls and other neurodegenerative diseases, or differentiate between clinical, genetic or pathologic 
subtypes. Staging biomarkers should allow us to assess disease severity and to discriminate between 
presymptomatic, prodromal, and early or late symptomatic stages. Pharmacodynamic biomarkers are 
important for evaluating the biological and clinical effect of future therapeutic interventions. Predicting 
the underlying pathology in FTD (tau versus TDP-43) is one of the greatest challenges, as this will be 
essential when specific disease-modifying interventions become available. Ideally, these interventions 
should be applied at an early stage when only minimal neuronal damage is present, underpinning the need 
for early biomarkers; at-risk subjects from families with genetic FTD form the ideal study population for 
detecting these earliest changes.  
In this review we focus on fluid and neuroimaging biomarkers in FTD. We discuss previous work on 
biomarkers with its current application in clinical practice and we highlight the development of new, 
promising biomarkers. 
Neuroimaging biomarkers 
Most FTD imaging studies have focused on structural changes by assessing grey matter atrophy, while 
more recent studies have been directed towards studying white matter integrity using diffusion tensor 
imaging (DTI), which is probably more sensitive for the earliest changes in FTD. In neurodegenerative 
diseases in general, structural abnormalities are often preceded by functional changes, and in the 
following section, we describe both the structural and functional changes found with different imaging 
modalities. 
Structural changes 
Grey matter 
The majority of imaging studies in FTD have used volumetric T1 MRI to investigate changes in grey 
matter structure.7–10 This technique is used to measure brain volume (and longitudinally, changes in that 
volume i.e. the rate of brain atrophy) as well as the volume of specific regions of interest within the brain, 
for example the frontal lobe or hippocampus. Several post-processing analytic techniques have also been 
applied to T1 imaging e.g. investigation of changes at the voxel level (e.g. voxel-based morphometry) or 
measurement of cortical thickness (e.g. Freesurfer), each providing an alternative way of investigating 
grey matter loss in the brain.  
On an individual patient level, semi-quantitative assessment of atrophy by visual rating scales performed 
by experienced dementia experts, has provided a good diagnostic performance to discriminate FTD from 
AD (where more posterior cortical involvement is seen) with a specificity of 81%.11  
Also clinical, genetic and pathological syndromes of FTD can to some degree be distinguished by distinct 
and dissociable patterns of grey matter atrophy at group level (Figure 2). Clinically, bvFTD is associated 
with frontal, temporal, insula and anterior cingulate atrophy, with earliest involvement of frontal 
paralimbic cortices and insula in mild bvFTD.12–14 Cluster analyses suggest that there may be four 
anatomical forms of bvFTD with frontal-dominant, temporal-dominant, frontotemporal and distributed 
temporofrontoparietal subtypes.15,16 However, these analyses have underplayed the involvement of 
subcortical structures in bvFTD, and it is clear that as the disease progresses, atrophy of the hippocampus, 
amygdala, basal ganglia and thalamus occurs.14,17 In the PPA syndromes, svPPA is associated with 
(commonly left-sided) asymmetrical anteroinferior temporal lobe atrophy, nfvPPA with left-sided 
predominant inferior frontal and insula involvement, and lvPPA with left temporo-parietal junction 
loss.18,19 Over time the extent of atrophy progresses not only within the same hemisphere but also starts to 
involve the opposite hemisphere in each of the PPA syndromes.20–22 In the genetic forms of FTD, GRN 
mutations are associated with asymmetrical fronto-temporo-parietal atrophy, MAPT mutations with 
relatively symmetrical involvement of the anteromedial temporal and orbitofrontal lobes, and C9orf72 
expansions with a symmetrical more widespread pattern of atrophy together with involvement of the 
thalamus and superior cerebellum.16,23–26 As with the clinical and genetic subtypes, whilst there are group-
level patterns, it has been difficult to distinguish individuals with specific pathological forms of FTD 
purely using structural T1 imaging, nor has it been possible to distinguish those with FTLD-TDP from 
FTLD-tau.9 Patients with FUS pathology generally present with prominent caudate atrophy, accompanied 
by orbitofrontal, anteriomedial temporal, anterior cingulate, and insula atrophy.27,28  
Across clinical, genetic and pathological forms of FTD, less work has been done on longitudinal changes 
in grey matter loss. However it is clear that there are variable rates of atrophy in different groups, with 
some being relatively fast (e.g. those with GRN mutations), and some very slow (a subgroup of patients 
with C9orf72 repeat expansions).29 If longitudinal structural imaging would be used for monitoring in 
clinical trials, sample size estimations show that focal atrophy rates, e.g. temporal lobe in svPPA, would 
allow a smaller sample than whole brain atrophy rates (reviewed elsewhere).7 
Findings from a number of small studies of those at-risk for genetic FTD have been inconsistent, with 
some showing grey matter atrophy prior to onset of symptoms and others not. However, a recent large 
multicenter analysis from the GENFI study reported the presence of atrophy at least 10 years prior to 
expected symptom onset (Figure 3a), with different genetic groups showing different patterns: in MAPT 
mutations, atrophy was noted first in the hippocampus and amygdala, followed by the temporal lobe and 
later the insula; in GRN carriers differences started in the insula, followed by temporal and parietal lobes 
and thereafter the striatum; in the C9orf72 group, changes were found very early (25 years before 
expected onset) in the subcortical areas (including thalamus), insula and occipital cortex, then the frontal 
and temporal lobes and later the cerebellum.30 Prominent asymmetry was found in GRN mutation carriers 
at five years before expected onset, but not in the other genetic subgroups. It is important to look at 
changes over time in this cohort, as small-scale longitudinal studies have shown more sensitivity, as 
illustrated by a significant reduction of left temporal cortical thickness in presymptomatic GRN carriers, 
without differences between presymptomatic- and non-carriers at baseline.31 
Diffusion tensor imaging 
DTI is a valuable non-invasive imaging technique for assessing white matter structure of the brain. It 
measures white matter microstructural integrity by determining the rate of diffusion (motion of water 
molecules) in different directions. Specific DTI metrics are thought to reflect different pathological 
changes in microstructure: a decrease in axial diffusivity (AxD) correlates with axonal degeneration; an 
increase in radial diffusivity (RD) indicates myelin breakdown; and a decrease of fractional anisotropy 
(FA), as a composite measure of both AxD and RD, represents more general nonspecific white matter 
integrity loss.32 Abnormalities in white matter diffusivity have been found to be more widespread and to 
grey matter atrophy in FTD, supporting the importance of white matter involvement in FTD.33–38 DTI 
may become a valuable biomarker as it has at least four potential applications, although currently, it has 
only been investigated at group level and not at single-subject level. 
Firstly, DTI is highly sensitive to differentiate FTD from controls and from other types of dementia, such 
as AD.32–36,38–45 White matter microstructure has shown to be more widespread affected in FTD compared 
with AD,32,34,39,40 with a high sensitivity (78%) and moderate specificity (68%) to discriminate these 
conditions by whole brain mean FA.34 White matter degradation co-occurs with frontal, temporal and 
insular atrophy in FTD, and is probably due to axonal degeneration associated with grey matter neuronal 
loss. It includes the anterior corpus callosum, bilateral anterior and descending cingulum and uncinate 
fasciculus tracts,42 which are part of motor, executive and language neural networks.  
Secondly, although white matter damage on DTI largely overlaps between subtypes, some distinctive DTI 
changes have been found in clinical, pathological and genetic FTD subtypes.33,35,36,38,40,42–44,46 The uncinate 
fasciculus, cingulum bundle and genu of the corpus callosum appear to be key tracts involved in the 
bvFTD disease process.34,41,44 PPA subtypes have shown different spatial patterns of white matter 
damage: left orbitofrontal and anterior temporal white matter (superior longitudinal fasciculus) in 
nfvPPA; asymmetric (mostly left) changes in the anterior and inferior temporal white matter (including 
the inferior longitudinal fasciculus), and bilateral uncinate fasciculi in svPPA; and more posterior 
abnormalities such as the posterior region of the left inferior longitudinal fasciculus in lvPPA.33,35,36,38,42–44 
DTI may have the potential to differentiate FTLD-tau from FTLD-TDP in vivo, as two studies have found 
more severe white matter integrity loss in FTLD-tau than FTLP-TDP.33,46 This parallels postmortem 
findings where tau-pathology is associated with marked axonal loss and glial tau-inclusions, and TDP-
pathology with greater grey matter neuronal loss than white matter pathology.46 Larger studies are needed 
for more conclusive observations before this can be used in individual patients. DTI studies have shown 
different patterns across genetic FTD patients subtypes: MAPT patients show consistent alterations in the 
uncinate fasciculus and right parahippocampal cingulum,34,41 whereas C9orf72-FTD patients tend to have 
more dorsal white matter tract pathology located in the cingulum, corpus callosum and the superior 
cerebellar peduncles.34,41  
Thirdly, though studies so far are limited, longitudinal DTI changes may be used to monitor the disease 
process and evaluate therapeutic effects in future clinical trials.41 Over time, DTI changes have been 
found to be more widespread than progression of grey matter atrophy, and have shown distinct patterns 
between clinical and genetic FTD subtypes which reflect different propagation of the neurodegenerative 
process within large scale brain networks.35 The bilateral uncinate fasciculus and paracallosal cingulum 
have shown the largest FA reduction in bvFTD,35,41 while left-to-right sided progression is seen in both 
svPPA and nfvPPA.35,43 In svPPA, longitudinal DTI changes extended to bilateral frontotemporal tracts, 
whereas changes in nfvPPA appeared to remain relatively focal.35,43 
Lastly, DTI as a biomarker may even be able to detect pathological changes before the onset of clinical 
symptoms and before grey matter atrophy in FTD. Decreased FA and increased RD in bilateral uncinate 
fasciculi (and forceps minor) have been found in a group of presymptomatic MAPT or GRN mutation 
carriers without grey matter atrophy (Figure 3b).37,47  
In conclusion, DTI appears to be a promising imaging biomarker for early diagnosis, and possibly to 
monitor the effect of pharmacological interventions in the future. To use DTI in the individual patient, 
reference data are essential to identify abnormal changes in white matter integrity, alike the use of 
automated quantitative MRI.48 The assembly of such normative data is however challenging due to 
variability across scanners and field strengths, as well as choice of DTI metric, tract, and method of 
analyzing (e.g. tracking or skeletonized). Region of interest analyses of specific tracts, such as the 
uncinate fasciculus, inferior – and superior longitudinal fasciculus, are likely to provide the best 
opportunity to move forward from the current group level studies to a single-subject analysis. 
Functional changes 
FDG-PET 
Positron emission tomography with [18F]fluorodeoxyglucose as tracer (FDG-PET) allows the 
visualization of alterations in brain metabolism, which precede grey matter atrophy in FTD and different 
forms of dementia.49–52 Distinct regional hypometabolism patterns on FDG-PET contribute to an accurate 
clinical diagnosis at an individual patient level, both by visual inspection and especially by quantitative 
assessment.53 Lower glucose metabolism, often asymmetric, in the orbitofrontal, dorsolateral and medial 
prefrontal cortex, anterior temporal poles and basal ganglia, is highly specific for bvFTD, with a 
sensitivity and specificity ranging between 80 and 95% for the differentiation from other dementia types 
and healthy controls.50,51,53–56 These patterns of hypometabolism are early features in the symptomatic 
stage, but also a few years before patients fulfill the criteria for probable bvFTD.50 As false-positive FDG-
PETs have been found in primary psychiatric disorders mimicking FTD, future quantitative assessment of 
metabolism patterns on PET may further increase its diagnostic value.54  
The patterns of focal hypometabolism vary between PPA subtypes and between genetic forms, and mirror 
the structural changes described above. svPPA is characteristically associated with asymmetrical bilateral 
temporal hypometabolism, while nfvPPA shows larger variability in hypometabolic patterns of the left 
inferior frontal gyrus, dorsolateral frontal cortex, anterior cingulate cortex, insula, and, occasionally, of 
the parietal cortex.57 Distinct FDG-PET patterns in PPAs may predict progression to specific dementia 
subtypes: bilateral temporo-parietal hypometabolism predicted conversion to AD, parietal 
hypometabolism to CBS, and involvement of basal ganglia, midbrain and cerebellum to PSP.57 
Longitudinal changes on FDG-PET may provide additional information on the patterns and speed of 
pathological spread.31,56 For example, svPPA patients show bilateral reduction of glucose metabolism in 
temporal lobes over time, which further extends to the anterior cingulate cortex and the posterior temporal 
lobes.58 When looking at genetic subtypes, GRN mutations are associated with asymmetric 
hypometabolism in frontal and temporal brain regions,31,59 ALS and/or FTD patients with C9orf72 
expansions with hypometabolism in the limbic system, basal ganglia and thalamus,60 and MAPT 
mutations with hypometabolism in the medial temporal lobe, frontal and parietal cortices.24 
Interestingly, FDG-PET already reveals abnormalities in the presymptomatic stage, and may serve as a 
surrogate endpoint in future therapeutic trials; asymmetric hypometabolism was found in frontal and 
temporal lobes in asymptomatic GRN carriers preceding the onset of clinical symptoms and of grey 
matter atrophy.31,59  
Arterial spin labeling 
Arterial spin labeling MRI (ASL) measures brain perfusion non-invasively by magnetically labeling water 
protons in arterial blood, which creates an endogenous tracer of cerebral blood flow (CBF).61 Brain 
perfusion measured by ASL correlates very well with metabolism measured by FDG-PET,51,53 but has 
several advantages over FDG-PET: it can be combined with other MRI techniques in a single session, it is 
non-invasive, has no radiation exposure, is widely available and is less costly.62  
ASL has shown hypoperfusion in the insula, the amygdala and several parts of the medial frontal lobes, 
including the anterior cingulate, in FTD patients.51,53,63–65 It differentiated bvFTD from AD at an early 
phase, with areas under the curve of up to 0.87 for CBF in specific frontal or parietal regions.51,53,63 In two 
comparative studies, the regions of hypoperfusion of ASL-MRI largely overlapped with those of 
hypometabolism on FDG-PET scans,51,53  and diagnostic performance when distinguishing bvFTD from 
AD and controls, was similar for both modalities.53  
ASL may also be an early biomarker in the preclinical stage of genetic FTD. Presymptomatic GRN and 
MAPT mutation carriers have showed significantly stronger CBF decrease over time than controls (Figure 
3c), independent of grey matter atrophy, in widespread frontal, temporal, parietal, and subcortical regions, 
with the strongest perfusion decline in subjects who converted to the disease stage.62 Some regional ASL 
changes may be specific for particular gene defects, as hypoperfusion may extend into posterior temporal 
and parietal regions in GRN mutation carriers.62  
Resting-state fMRI 
Resting-state functional MRI (RS-fMRI) is a potential biomarker for early diagnosis and disease staging 
as it measures intrinsic functional connectivity between brain regions on MRI, which can be detected as 
synchronous patterns of spontaneous low frequency fluctuations in blood-oxygen-level-dependent signals. 
RS-fMRI is a safe, non-invasive, and repeatable tool, which is sensitive to detecting changes in brain 
functional connectivity before the onset of clinical symptoms or atrophy on group-level.37,66,67 Decreased 
connectivity between the frontoinsula and anterior cingulate cortex, as part of the salience network, is the 
most consistent finding in FTD,67–71 while other studies found normal or increased connectivity.72–74 
Inconsistent differences (both increased and decreased connectivity) were found for the default mode 
network in FTD.67–69 The discrepancies in functional connectivity may partly be explained by cohort and 
scanner differences and the wide variation in analytical methods, such as independent component 
analyses, seed- or region-of-interest approaches, or regional homogeneity analyses.66,68,72,74,75  
Specific network alterations are also found between clinical and genetic subtypes of FTD. Reduced left 
temporal lobe connectivity is found in svPPA,76,77 attenuated connectivity in both salience and 
sensorimotor networks in C9orf72 bvFTD-patients,26 and reduced left frontal connectivity in GRN 
mutations.78 In the presymptomatic phase, RS-fMRI may be sensitive to detecting connectivity 
differences, as altered (both reduced and increased) frontoinsula and/or ACC connectivity have been 
reported in presymptomatic mutation carriers.37,66,78,79  
Amyloid and Tau PET tracers 
Several other tracers may serve as diagnostic biomarkers in the differential diagnosis of FTD and AD, and 
between different pathological subtypes of FTD. PET with an amyloid tracer such as Pittsburgh 
compound B (PiB) tracer is a robust and sensitive biomarker for detecting amyloid-β deposits, indicating 
AD pathology, in vivo,80 and bvFTD, svPPA and nfvPPA are mostly PiB-negative. Most lvPPA cases 
represent atypical AD with a PiB binding pattern similar to that of AD,81–83 while lvPPA with negative 
PiB-PET is accompanied by structural and FDG-PET abnormalities supporting underlying FTLD 
pathology.83,84 Unexpected positive PiB-PET in FTD cases may result from mild co-incidental AD 
pathology, not related to the clinical FTD presentation.85 
Several tracers have been developed to visualize tau pathology in vivo however the ideal ligand that 
captures the wide range of tau pathology has not yet been developed. Distinct ligand selectivity to the 
different tau isoforms and their intracellular aggregation requires probably the application of different tau 
ligands.86 Tau PET with the 18F-AV-1451 ligand has shown increased uptake in the temporal cortex, 
frontal cortex, and basal ganglia in FTD patients with an R406W MAPT mutation, which is associated 
with both 3-repeat- and 4-repeat-tau pathology. In these patients, higher regional 18F-AV-1451 uptake 
correlated with lower glucose metabolism and with postmortem burden of tau pathology.87 However, 
binding of 18F-AV-1451 appears poorer in conditions with only 4-repeat-tau, as shown by a lack of 
correlation with postmortem tau pathology in PSP.88,89 A recent study using postmortem material reported 
that 11C-PBB3 was more robust for capturing wide-range tau pathologies, including both 3- and 4-repeat-
conditions.90 Also the 18F-THK-5351 ligand showed promising results in the 4-repeat-diseases PSP and 
CBS both on postmortem tissue as in vivo.91,92 Once validated, tau PET may become effective in 
diagnosing underlying tau pathology as well as providing a surrogate marker for trials with anti-tau 
therapeutics.86  
Summary of imaging biomarkers 
Grey matter atrophy and FDG-PET hypometabolism are validated diagnostic biomarkers showing 
relatively consistent changes at group level between studies, and are clinically applied at an individual 
level for the differentiation between FTD and AD or controls (Table 1). More work needs to be done on 
the use of imaging modalities in distinguishing FTD subtypes at an individual level, with larger studies of 
longitudinally acquired imaging data, before this can be used as an outcome measure to monitor disease 
progression in clinical trials. 
We expect new modalities like DTI, ASL and RS-fMRI to become valuable biomarkers in clinical 
practice, especially due to their sensitivity, enabling early diagnosis and their potential use in longitudinal 
monitoring (Table 1). Crucial to their implementation is the harmonization across different centers, as 
there is considerable variation across scanners and protocols. For example in ASL, the diversity of 
scanning protocols influences perfusion quantification, which may be overcome by proposed international 
standardization of protocols.61 Additionally, integrating different types of information by combining 
imaging modalities holds great promise for the future, as demonstrated by multimodal analyses that have 
improved the classification between FTD and AD, 40,45,52,65,93,94 and between clinical FTD subtypes. 94 
Fluid biomarkers 
Alterations in specific protein concentrations in different human fluid compartments may reflect 
pathophysiological changes of disease processes. The close vicinity of CSF to the brain offers a high 
chance of revealing disease-specific biomarkers. Subsequent validation in blood of such biomarkers 
would be of great value, being minimally  invasive and enabling repeated measurements over time. 
Recent studies have demonstrated that brain specific proteins in neurodegenerative disorders can reliable 
be detected in blood by novel ultrasensitive assays (e.g. Single Molecule Array technology). The progress 
of these developments in the following years, offers a new window of opportunities for diagnosing, 
staging and monitoring FTD patients. In the next section, we will first review the currently applied CSF 
markers for differentiating FTD from AD, and then highlight promising (also blood-derived) biomarkers 
in sporadic and genetic FTD.   
CSF amyloid-β and tau 
The core CSF biomarkers for AD are phospho-tau181 (p-tau), total-tau (t-tau), and amyloid beta1-42 (Aβ1-
42); these represent the pathological changes in AD, being accumulation of hyperphosphorylated tau in 
neurofibrillary tangles, neuronal loss, and amyloid beta (Aβ) depositions in senile plaques respectively.95 
These biomarkers have comprehensively been validated to exclude AD in the diagnostic work-up of FTD, 
both in clinical cohorts and small pathologically confirmed case series, with higher p-tau and t-tau, and 
lower Aβ1-42 levels in AD than FTD patients.96 A high Aβ1-42:p-tau or Aβ1-42:t-tau ratio gives an especially 
good diagnostic performance when distinguishing FTD from AD (Aβ1-42:p-tau: specificity 80% and 
sensitivity 87%; Aβ1-42:t-tau: specificity 79%, sensitivity 89%). The use of ratios of other Aβ isoforms 
may improve diagnostic accuracy, especially when differentiating AD from vascular dementia and LBD, 
but also for distinguishing AD from FTD.97,98 
The core AD biomarkers are also valuable when differentiating between underlying AD or FTLD 
pathology in the differential diagnosis of PPA, in which an AD profile is often found in clinically 
diagnosed lvPPA patients as opposed to svPPA and nfvPPA patients.99–102 An AD CSF profile 
occasionally occurs in FTD cases, even in pathology proven cases; this may partly be explained by the co-
occurrence of AD pathology.103 Moreover, decreased Aβ1-42 levels were found in up to 25% C9orf72 
patients in a Finish cohort, but not in GRN patients, and to elucidate its pathophysiological significance, 
more clinicopathological and genetic studies are required.104–106 
Tau levels in CSF are not increased in FTD with underlying tau-pathology nor in patients with MAPT 
mutations, compared to tau-negative or sporadic FTD.107,108 Reduced p-tau:t-tau ratios have been found to 
be a specific biomarker to distinguish FTLD-TDP from FTLD-tau, although this appears to be driven by 
concomitant MND.109–112 Whether the increase of t-tau as abnormal axonal biomarker or reduction of p-
tau determines the reduced ratio, is not completely clear. In line with this hypothesis of axonal damage, 
the association of a reduced p-tau:t-tau ratio with survival is an interesting finding in one study.111  
Neurofilament proteins 
Neurofilament light chain (NfL) is probably the most promising fluid biomarker in FTD in the short term 
for disease monitoring and prognosis. Neurofilaments are the major constituent of the neuroaxonal 
cytoskeleton and play important roles in axonal transport and in the synaps.113 NfL is the most abundant 
and soluble neurofilament-subunit, and increased levels are thought to reflect axonal damage.  
NfL levels are 2.5-11 times higher in FTD than in controls and its clinical value especially lies in the 
correlation with disease severity and progression, survival, and cerebral atrophy (Figure 4).114–116,111,117–119 
CSF NfL is also increased, although to a lesser extent, in several other neurodegenerative diseases (e.g. 
ALS, AD, PSP, and vascular dementia), and should therefore be combined with disease specific 
biomarkers.114,117,120–122 NfL levels are equally elevated among FTD subtypes bvFTD, nfvPPA and svPPA, 
and are strongly increased in FTD with MND.111,114–116,118 High CSF NfL levels were found in patients 
with TDP pathology compared with tau pathology, which was largely driven by ALS co-occurrence.111,118 
In particular, high NfL levels were found in FTD patients with GRN mutations, a large variation was 
found in C9orf72 patients (ranging from high levels in concomitant MND to low levels in patients who 
slowly progress), and MAPT patients had relatively low levels (Figure 4b).115 Interestingly, 
presymptomatic genetic FTD carriers show normal NfL levels in CSF and blood, with a sharp increase 
reported after conversion to the disease stage in two converters (Figure 4b).115 It is unknown whether and 
how NfL levels fluctuate over time in FTD, but available longitudinal data in ALS have shown stable NfL 
levels or a minor increase over time.120,123 The recent finding of the strong correlation of NfL levels 
between CSF and serum makes this biomarker measurable in blood and especially suitable for repeated 
measurements.115,119 
In mouse models of neurodegenerative diseases (tau, Aβ, and α-synuclein), NfL increase coincided with 
the onset and progression of brain pathology, and blocking Aβ lesions attenuated the NfL increase.124 This 
observation suggests that we can use NfL to monitor treatment response in neurodegenerative diseases. In 
conclusion, NfL is a promising, non-invasive biomarker for disease staging, monitoring, and prognosis in 
FTD. Longitudinal studies in FTD need to be conducted to gain insights into the role of NfL as a 
progression marker.  
Genetic-specific biomarkers  
Progranulin 
Progranulin (PGRN), a multifunctional protein, plays an important role in neurite outgrowth and 
inflammation.125 Due to haploinsufficiency, pathogenic loss of function mutations in GRN reduce blood 
and CSF PGRN to 25-40% of normal levels.125–129 Blood or CSF PGRN are diagnostic biomarkers for 
pathogenic GRN mutations, as they discriminate (presymptomatic and symptomatic) carriers from non-
carriers with a sensitivity and specificity of up to 100% (Figure 5a).128,129 In line with this, blood PGRN 
levels can help to assess the pathogenicity for unclassified variants in GRN. Currently, therapeutic trials 
are focusing on enhancing PGRN expression, for example by histone deacetylase inhibitors.130 In these 
trials, target engagement is assessed using blood PGRN levels, as they appear to be constant over 
time.129,131 However, blood and CSF PGRN are differentially regulated, as demonstrated by the moderate 
correlation between these compartments in GRN mutation carriers, and therefore CSF should be sampled 
as well.129 PGRN levels thus provide a good pharmacodynamic biomarker, but do not reflect the extent of 
neurodegeneration in the brain, wherefore different additional biomarkers are needed as surrogate 
endpoints. 
Dipeptide-repeats in C9orf72 
C9orf72 repeat expansions are known to be transcribed to expanded G4C2 RNA, which forms RNA foci 
and in parallel is translated into proteins of repeating dipeptides (dipeptide-repeats, DPRs) by repeat-
associated non-ATG translation.132 Both RNA foci and DPRs are believed to have a key role in the 
pathophysiology of this disorder.132–134 An elevated poly(GP) level, one of the DPRs, has been found in 
the CSF of patients with C9orf72 repeat expansions, and also in presymptomatic mutation carriers (Figure 
5b+c).134,135 Moreover, poly(GP) levels remained relatively constant over time, which support the use of 
poly(GP) as a potential pharmacodynamic biomarker in future therapeutic trials.135 Antisense 
oligonucleotides binding to G4C2 RNA have been shown to reduce extracellular poly(GP) in human cell 
models and to reduce RNA foci and DPRs, as well as CSF poly(GP) levels, in mice harboring a G4C2 
expansion.133–135 This implicates that poly(GP) may be a potential target engagement biomarkers to 
measure biochemical responses to treatment with these agents.134,135 As poly(GP) levels did not correlate 
with age at onset, disease duration, severity or survival, future clinical trials in patients with C9orf72 
repeat expansions may benefit from the combination of poly(GP) levels as pharmacodynamic marker and 
NfL as a prognostic marker.  
Potential future fluid biomarkers  
As FTLD with phosphorylated TDP-43 (pTDP-43) aggregates constitutes one of the major pathological 
subgroups of FTLD, pTDP-43 protein levels in CSF or blood would be an interesting biomarker, but to 
date, results have been contradictory. Strongly elevated CSF pTDP-43 levels have been found in a small 
series of C9orf72 and GRN patients, but did not differ between FTD with TDP-43 and tau pathology in a 
pathology-proven cohort.112,136 Quantification in CSF is challenging due to low concentrations, various 
isoforms and antibodies,112,137 and the development of better TDP-43 assays is warranted.  
Neuroinflammation plays an important role in FTD and other neurodegenerative diseases, as it represents 
both a consequence of and a trigger for pathology.138 Microglia are the major immune component of the 
central nervous system, and are activated by damaged neurons and misfolded proteins resulting in the 
initiation of a chronic inflammatory response.138 In a study on sporadic FTD (and AD) patients, reduced 
levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM2, a protein involved in 
inflammation and phagocytosis and mainly expressed by microglia) were found.139 CSF levels of YKL-40 
(chitinase-3 like-1, cartilage glycoprotein-39), an inflammatory protein produced by astrocytes, have been 
found to be elevated in pathologically proven FTD, but also in AD, vascular dementia, normal aging and 
other neurological disorders such as multiple sclerosis.140–142 This is also true for glial fibrillary acidic 
protein, an astrocytic cytoskeletal protein, which was found to be increased in both FTD and other 
dementia types.143 Recently, a strong link between GRN mutations and microglial activation has been 
established, with excessive complement production leading to synaptic pruning.144 Promising data suggest 
that proteins involved in complement activation are potential biomarkers to track disease progression in 
GRN mutation carriers.144 
Various changes in cytokines (primarily pro-inflammatory, e.g. MCP-1, IL-6, TNF-α) have been found in 
FTD, but these also reflect aspecific mechanisms, as they are also present in AD.145–150 The role of several 
neuropeptides has been extensively reviewed elsewhere,151 for example neurogranin, a postsynaptic 
protein involved in synaptic plasticity, which was lower in FTD patients than in controls and AD 
patients.141 Larger, pathologically proven and genetically determined cohorts are needed for validation of 
these cytokines and neuropeptides.  
Novel approaches are focusing on enriched protein fractions and microRNAs (miRNAs) in exosomes. 
Exosomes are vesicles secreted from cells; they facilitate intercellular communication and are enriched 
sources of biomolecules. The value of examining exosomes is supported by a small study reporting 
reduced synaptic protein levels in blood-derived exosomes in FTD.152 miRNAs regulate gene expression, 
and seem to play a role in TDP-43 and FUS pathology, but have not yet been studied as biomarkers in 
FTD.153 
Summary of fluid biomarkers 
Several fluid biomarkers provide currently usable (e.g. core AD biomarkers) or promising biomarkers in 
FTD (e.g. NfL) (Table 1). It is likely that combinations of CSF metabolites will yield more information 
than single markers alone, for example a biomarker panel achieved a high sensitivity to differentiate 
TDP43- from tau-pathology.145 In general, more validation and longitudinal data is needed to determine 
the full potential of these and other candidates. Lastly, it is important to harmonize collection and analysis 
of fluid biomarkers, as their levels can be influenced by multiple pre-analytical and analytical factors, 
including sampling and storage methods, and choice and implementation of assays.154 Multicenter 
standardization of these procedures and quality control programs will facilitate collaborative research and 
the implementation of new fluid biomarkers in clinical practice. 
Conclusions 
Neuroimaging and fluid biomarkers are becoming increasingly important in the context of future 
therapeutic interventions in both sporadic and genetic forms of FTD. Several imaging and CSF 
biomarkers are already established (e.g. grey matter atrophy, FDG-PET and CSF AD biomarkers) and 
being used in clinical practice, often in the differential diagnosis of FTD. The field is moving forward in 
identifying gene-specific markers and finding new biomarkers for staging, predicting underlying 
pathology and monitoring treatment responses. For example, DTI has shown a good performance in 
discriminating FTD from AD, as well as demonstrating early pathological changes; NfL can differentiate 
FTD from controls and is a promising staging and prognostic biomarker for FTD; and genetic specific 
biomarkers (PGRN and DPRs) may be valuable for assessing target engagement in therapeutic trials. 
Importantly, combinations of biomarkers will add value in order to accurately define the FTD subtype, 
disease onset, as well as to  monitor progression and eventually treatment response. For example, in a 
PGRN-enhancing trial, target engagement can be assessed by PGRN levels, but additional surrogate 
endpoints are needed to assess the physiological effect (i.e. reduction of neurodegeneration).  
Most alterations of these novel biomarkers have currently been demonstrated on group level and need to 
be validated for individual subjects, which is challenging due to the relative rarity of FTD. Multicenter 
research can help to increase statistical power and prove clinical utility; prime examples of longitudinal 
observational cohorts include GENFI (Genetic Frontotemporal Dementia Initiative), ARTFL (Advancing 
Research and Treatment for Frontotemporal Lobar Degeneration Consortium), LEFFTDS (Longitudinal 
Evaluation of Familial Frontotemporal Dementia Subjects), and a collaboration including these consortia 
in the FPI (FTD Prevention Initiative). Research in genetic FTD provides a unique window to study the 
earliest disease effects and therefore offers a high chance to identify valuable biomarkers. Despite 
similarities between genetic and sporadic FTD, the use of biomarkers identified in genetic cases requires 
validation in sporadic cohorts as biomarker profiles and trajectories may differ, alike in AD.155 
Interestingly, it is increasingly emphasized that FTD, classically considered as an early-onset dementia, 
frequently manifests after the age of 65 years and may include clinical features suggestive of AD.156,157 
This stresses the need of diagnostic biomarkers specific for FTD, as the co-occurrence of Alzheimer 
pathology increases with age. The value of FTD biomarkers in different age groups with comorbidities 
remains to be elucidated. Additionally, future research should focus on combining biomarkers (both fluid 
and imaging) to make optimal use of these modalities, as well as on harmonization of collection and 
analysis protocols to facilitate dissemination in research and clinical practices. 
Key points 
 Most of the validated biomarkers in frontotemporal dementia (FTD) (e.g. grey matter atrophy, 
FDG-PET and CSF amyloid beta1-42, phospho-tau181, and total-tau) are used to differentiate FTD 
from Alzheimer’s disease or controls 
 New imaging biomarkers, like arterial spin labeling and diffusion tensor imaging, appear to be 
more sensitive to show subtle changes that precede grey matter atrophy in FTD, providing a 
potential role in diagnosis and monitoring 
 Promising upcoming fluid biomarkers are neurofilament light chain for staging, monitoring, and 
prognosis in all FTD subtypes, and dipeptide and progranulin proteins for target engagement in 
gene-specific forms 
 There is still a need of reliable biomarkers to differentiate between tau- and TDP-pathology in 
light of trials on disease-modifying treatments 
 Future research should focus on the multimodal combination of fluid and imaging biomarkers, as 
well as on the harmonizing of collection and analysis protocols 
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Text Boxes: 
Text Box 1. Main clinical characteristics of FTD 
• BvFTD (behavioral variant FTD): 
– Personality and behavioral changes (including disinhibition, apathy, loss of sympathy, 
perseverative behavior, abnormal appetite), and executive dysfunction 
• Primary progressive aphasia (PPA): progressive prominent language difficulties that impair 
daily living. Subtypes: 
– Semantic variant PPA (svPPA): fluent speech characterized by anomia and impaired 
single word comprehension 
– Non-fluent variant PPA (nfvPPA): non-fluent speech with agrammatism and/or apraxia 
of speech 
– Logopenic variant (lvPPA): non-fluent speech with word-finding difficulties in 
spontaneous speech and in repetition 
 
Text Box 2. Biomarkers – requirements and applications 
Requirements: (adjusted from 6) 
• Able to detect fundamental feature of FTD pathology 
• Validated in neuropathological confirmed FTD 
• Precise 
• Reliable 
• Non-invasive 
• Simple to perform 
• Inexpensive 
Applications: 
• Prediction 
• Diagnostic 
• Staging 
• Monitoring: 
– Disease progression 
– Treatment response (surrogate endpoint, target engagement) 
• Prognostic 
Figure legends: 
Figure 1. Clinical, pathological and genetic spectrum of FTD. Genetic forms have predictable pathology: 
GRN and C9orf72 mutations show TDP pathology whereas MAPT mutations show tau pathology. In 
contrast, across the clinical spectrum of FTD variable underlying pathologies and genetic forms can be 
found. ALS and FTD-MND phenotypes is infrequently caused by FTLD-FUS pathology or FUS 
mutations, for simplicity this is not included in the figure. Adapted with permission from Seelaar et al.158 
ALS: amyotrophic lateral sclerosis, bvFTD: behavioral variant FTD; C9orf72: C9orf72 repeat 
expansions; CBD: corticobasal degeneration; FTD: frontotemporal dementia; FTLD: frontotemporal lobar 
degeneration; FUS: fused in sarcoma; GRN: progranulin gene mutations; MAPT: microtubule-associated 
protein tau mutations; MND: motor neuron disease; nfvPPA: non-fluent variant PPA; PPA: primary 
progressive aphasia; PSP: progressive supranuclear palsy; svPPA: semantic variant PPA; TARDP: 
transactive response DNA-binding protein gene; TBK-1: TANK-binding kinase 1 gene; TDP-43: 
transactive response DNA-binding protein 43; VCP: valosin containing protein 
Figure 2. Characteristic patterns of grey matter atrophy (highlighted) in different clinical and genetic 
subtypes of FTD. bvFTD patients show prominent frontal, insular and anterior cingulate atrophy; typical 
temporal atrophy in svPPA is asymmetrical (most often left); nfvPPA patients show left frontal and 
insular atrophy; in patients with underlying FUS-pathology, nucleus caudatus atrophy is pronounced; 
GRN patients often show asymmetrical fronto-temporo-parietal atrophy; C9orf72 present mostly with a 
generalized symmetrical atrophy; and MAPT patients show marked symmetrical temporal atrophy. 
bvFTD: behavioral variant FTD; C9orf72: C9orf72 repeat expansions; FTD: frontotemporal dementia; 
FUS: fused in sarcoma underlying pathology; GRN: progranulin mutations; MAPT: microtubule-
associated protein tau mutations; nfvPPA: non-fluent variant PPA; PPA: primary progressive aphasia; 
svPPA: semantic variant PPA; 
Figure 3. Imaging abnormalities in the presymptomatic stage of genetic FTD. (a) Grey matter changes 
adopted from the GENFI study: standardized difference between all (presymptomatic + symptomatic) 
mutation carriers and non-carriers in cortical grey matter volumetric imaging measures (Y-axis) versus 
estimated years from expected symptoms onset (X-axis); (b) DTI changes: decreased fractional 
anisotropy in presymptomatic GRN and MAPT mutation carriers versus controls in the uncinate 
fasciculus; and (c) ASL changes: lower cerebral blood flow in presymptomatic GRN mutation carriers 
than in controls cross-sectionally at follow-up. Reproduced with permission from (a) Rohrer et al.,30 (b) 
Dopper et al.,37 and (c) Dopper et al.62  
Figure 4. CSF neurofilament light chain levels. (a) CSF NfL levels in clinical FTD subtypes and other 
neurodegenerative disease; horizontal lines represent medians and filled squares represent patients with 
concomitant MND; (b) CSF NfL levels in presymptomatic and symptomatic genetic FTD of the three 
major genes (GRN, C9orf72 and MAPT), including two subjects who converted from the presymptomatic 
to symptomatic stage (connecting line), filled squares represent patients with concomitant MND; and (c) 
Kaplan-Meier survival curves stratified for CSF NfL levels in tertiles; upper light-grey line represents low 
CSF NfL levels, middle dark-grey line represents intermediate CSF NfL levels, and lower black line 
represents high CSF NfL levels. Adapted with permission from (a) Scherling et al.,114 and (b+c) Meeter et 
al.115 Permission obtained from Scherling and Meeter; permission necessary from (a) Annals of 
Neurology, and (b+c) Annals of Clinical and Translational Neurology. 
AD: Alzheimer’s disease; bvFTD: behavioral variant FTD; C9orf72: C9orf72 repeat expansions; CBS: 
corticobasal syndrome; CSF: cerebrospinal fluid; GRN: progranulin mutations; MAPT: microtubule-
associated protein tau mutations; MND: motor neuron disease; NC: normal controls; NC2: healthy at risk 
for a genetic mutation subjects; NfL: neurofilament light chain; nfvPPA: non fluent variant PPA; PD: 
Parkinson’s disease; PPA: primary progressive aphasia; PSP: progressive supranuclear palsy; svPPA: 
semantic variant PPA. 
Figure 5. Genetic specific fluid biomarkers. (a) plasma PGRN levels are significantly lower, without 
overlap, in carriers of GRN mutations (presymptomatic carriers, ASX GRN+, and symptomatic carriers, 
SX GRN+) than in controls (GRN-), [(b+c) confidential panels, will be published in March] (b) CSF 
poly(GP) levels are significantly higher in C9orf72 repeat expansion carriers (C9+) than non-carriers 
(C91), (c) already in the presymptomatic stage (ASX) when compared to the symptomatic stage (SX). 
Adapted with permission from (a) Meeter et al.,129 and (b+c) adopted from Gendron et al.135 Horizontal 
red lines represent the sample medians in a given group. This figure is optional; in our opinion it is very 
illustrative, however it exceeds the maximum of 7 display items. Lay-out, including terminology, can be 
adjusted once the poly(GP) figures are published and permission to adapt is obtained. 
ASX: asymptomatic (presymptomatic) carrier; C9+: C9orf72 repeat expansion carrier; C9-: non-carriers 
of a C9orf72 repeat expansion; CSF: cerebrospinal fluid; GRN+: progranulin gene mutation carrier; 
GRN-: non-GRN-carriers; PGRN: progranulin protein; poly(GP): glycine-proline repeating protein; SX: 
symptomatic carrier 
Tables 
Table 1. Potential biomarkers in FTD and their application in clinical practice 
Biomarker Application 
  
Diagnosis 
Staging and monitoring 
disease progression 
Prognosis 
Monitoring 
treatment 
response 
FTD vs AD 
FTD subtypes 
(clinical/genetic
/pathologic) 
Symptomatic 
Presymptom
atic 
 
Imaging biomarkers 
Grey matter atrophy 
DTI 
FDG-PET 
Tau-PET 
ASL 
RS-fMRI 
++ 
++ 
++ 
+ 
++ 
+ 
++ 
+ 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
 
 
+ 
+ 
+ 
 
 
 
Fluid biomarkers 
p-tau, t-tau and Aβ1-42  
NfL  
PGRN 
Poly(GP)  
++ 
+ 
 
 
+ 
+ 
++ 
+ 
 
++ 
 
 
 
+ 
 
 
+a 
++ 
 
 
 
+ 
+ 
+ 
Summary of current or potential biomarkers and their applications that are reported thus far. ++ = robust biomarker, replicated in 
independent cohorts, + = potential biomarker.  
ap:t-tau ratio. Aβ1-42: amyloid beta1-42; AD: Alzheimer’s disease; ASL: arterial spin labeling; DTI: diffusion tensor imaging; 
FDG-PET: [18F]fluorodeoxyglucose positron emission tomography; FTD: frontotemporal dementia; NfL: neurofilament light 
chain; PGRN: progranulin protein; poly(GP): glycine-proline repeating protein; p-tau: phospho-tau181; RS-fMRI: resting-state 
functional magnetic resonance imaging; tau-PET: tau positron emission tomography; t-tau: total-tau 
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